CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Chardan Downgrades Tenax Therapeutics to Neutral From Buy, Adjusts Price Target to $5 From $27

Negative
AI Analysis

Summary

Chardan downgraded Tenax Therapeutics from Buy to Neutral and reduced its price target from $27 to $5 per share.

Importance:4/10
Sentiment:
-0.80
analyst_downgradeprice_target_reductionrating_change
Related Companies

Read the original article

Published by yahoo_finance on August 11, 2026 3:49 PM

Read Original